| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424202100 | Combination of antigens from multiple viral species (e.g., multivalent viral vaccine, etc.) | 66 |
| 20080206278 | Vaccine - Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus. | 08-28-2008 |
| 20080213304 | Methods of Treating and Preventing Neurological Symptons Caused by Avian Reovirus and Novel Associated Characteristics - Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms. | 09-04-2008 |
| 20080260778 | Method of Vaccination Against Testicular Bvdv Infection - The methods of the invention relate to methods for preventing testicular infection by bovine viral diarrhea virus by immunizing susceptible male animals against infection. | 10-23-2008 |
| 20080267992 | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine - The present invention relates to the field of biological engineering technology, specifically, to a SARS virus vaccine with adenovirus carrier, preparation method thereof and use of SARS virus S gene for preparation of severe acute respiratory syndrome (SARS) virus vaccine. | 10-30-2008 |
| 20080267993 | AIDS vaccines - The invention provides vaccination protocols for administering immunogens to a primate host in order to promote the formation of neutralizing antibodies (NAbs) against primate immunodeficiency viruses. In some embodiments, the vaccination protocols comprise the step of administering to a primate host a first immunogen comprising at least one primate immunodeficiency virus Envelope (env) sequence having a first set of consensus glycosylation sequences, followed by a second immunogen comprising at least one primate immunodeficiency virus env sequence having a second set of consensus glycosylation sequences, wherein the differences between the first set of consensus glycosylation sequences and the second set of consensus glycosylation sequences comprise differences in consensus glycosylation sequences observed in HIV isolates obtained at different time points of a natural infection. | 10-30-2008 |
| 20080317776 | Vaccines Containing Viruses Involved in Avian Malabsorption Syndrome and Methods of Administration Therefor - The causative agent(s) of Avian Malabsorption Syndrome (MAS) are isolated and used to prepare vaccines for use in the prevention of diseases resultant therefrom. The vaccines contain at least two avian viruses—the reovirus and adenovirus—and optionally include another virus which inflicts poultry. The viruses may be live, attenuated live, or inactivated when incorporated into the vaccine. The vaccine itself may be administered in ovo, to new-born or growing chicks, or to adult fowl. | 12-25-2008 |
| 20090074812 | Influenza M2 protein mutant viruses as live influenza attenuated vaccines - A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus. | 03-19-2009 |
| 20090175904 | Expressing hepatitis B virus surface antigen for vaccine preparation - HBsAg is expressed in a | 07-09-2009 |
| 20090191238 | Method for producing yeast expressed HPV types 6 and 16 capsid proteins - Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice. | 07-30-2009 |
| 20090246223 | Inactivated Chimeric Vaccines and Related Methods of Use - Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other embodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic composition. Other embodiments comprise methods of preparing a vaccine or immunogenic composition for the treatment or prevention of viral infection in such animals. | 10-01-2009 |
| 20100015177 | Method for Preserving Viral Particles - A method for preserving viral particles comprises: (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said viral particles wherein the concentration of polyethyleneimine is 15 μM or less based on the number-average molar mass (M | 01-21-2010 |
| 20100068223 | Storage of Influenza Vaccines Without Refrigeration - Antigens from individual influenza virus strains are not refrigerated before being combined to make multivalent influenza virus vaccines. Moreover, influenza vaccines are not refrigerated between packaging and administration. Thus the need for refrigeration is minimized, and the cold-chain does not have to be maintained between vaccine manufacture and administration. | 03-18-2010 |
| 20100068224 | Method for Producing Viral Vaccine and Therapeutic Peptide Antigens - A method of producing viral antigens for use in a vaccine or therapeutic composition against infection by a virus, and a composition produced thereby, are disclosed. The method is applicable to viruses having a plurality of subtypes whose protein sequences for at least one viral protein or polyprotein are known. Regions of a selected viral protein that (i) are known or predicted to bind to MHC proteins in host antigen-presenting cells, and (ii) have a moderate amino acid variability within the virus subtypes are systematically varied in amino acid sequence, and tested for enhanced binding to MHC proteins. The composition includes those peptides having the highest binding affinity for MHC proteins. | 03-18-2010 |
| 20100098721 | METHODS AND COMPOSITIONS FOR PREPARING A UNIVERSAL INFLUENZA VACCINE - Compositions and methods for preventing and treating influenza virus infections are provided. Compositions include novel immunogenic compositions having at least one vector capable of expressing an antigenic component from four or more influenza viruses representative of the antigenic diversity of a target population of influenza virus strains. Compositions further include novel immunogenic compositions having at least four vectors, each vector capable of expressing a single antigenic component representative of the antigenic diversity of a target population of influenza virus strains. In other aspects of the invention, the immunogenic compositions also include one or more viral proteins (or antigenic portions thereof), or one or more live attenuated viruses, derived from the target population of influenza virus strains. The invention further provides methods for making a multi-valent influenza vaccine and methods for inducing an immune response in a subject against influenza viruses. | 04-22-2010 |
| 20100111996 | Papaya Mosaic Virus-Based Vaccines for Influenza - An antigen-presenting system (APS) comprising one or more antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. Specifically an APS comprising one or more influenza virus antigens is provided. The APS can be used, for example, as a vaccine against influenza. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PaPMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP). Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means. | 05-06-2010 |
| 20100119548 | METHOD FOR LIMITING THE GROWTH OF CANCER CELLS USING AN ATTENUATED MEASLES VIRUS - A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 10 | 05-13-2010 |
| 20100189741 | OIL-IN-WATER EMULSION INFLUENZA VACCINE - The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 μg HA or a low amount such as less than 15 μg HA. | 07-29-2010 |
| 20100203080 | Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof - The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine. | 08-12-2010 |
| 20100215692 | Dengue Chimeric Viruses - The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus. | 08-26-2010 |
| 20100255030 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 10-07-2010 |
| 20100260796 | Stabilizers for freeze-dried vaccines - The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions, which may comprise, inter alia, canine paramyxovirus. The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, for example, canine paramyxovirus, which may contain these stabilizers. Other aspects of the invention are described in or are obvious from the following disclosure, and are within the ambit of the invention. | 10-14-2010 |
| 20100278857 | Dendritic Cell Binding Proteins and Uses Thereof - The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided. | 11-04-2010 |
| 20100297169 | Novel Neutralizing Immunogen (NIMIV) of Rhinovirus and its Use for Vaccine Applications - The invention relates to methods and compositions for preventing or treating human rhinovirus infection. | 11-25-2010 |
| 20100297170 | VACCINES - The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R | 11-25-2010 |
| 20100316669 | VACCINE FORMULATION POTENTIATED BY THE COMBINATION OF DNA AND AN ANTIGEN - Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. | 12-16-2010 |
| 20100316670 | CHIMERIC SLE/DENGUE TYPE 4 ANTIGENIC VIRUSES - Embodiments described herein concern attenuated, St. Louis Encephalitis Virus/dengue virus type 4 antigenic chimeric viruses, which can be used to prepare immunogenic compositions, vaccines, and diagnostic reagents. Methods of making and using the foregoing are provided. | 12-16-2010 |
| 20110059127 | USE OF MUTANT HIV-1 PROTEASE OR SIV PROTEASE AS AN ADJUVANT - The present invention relates to a mutant HIV-1 (Human immunodeficiency virus-1) protease capable of effectively enhancing cell-mediated immune responses to DNA vaccination, and use of a nucleic acid encoding the same as a vaccine adjuvant. The mutant HIV-1 protease according to the present invention has inactivated or attenuated proteolytic activity, while retaining chaperone-like activity. When the mutant HIV-1 protease is used together with a DNA vaccine against the HIV-1 envelope protein or the HPV antigen (E6 or E7), cell-mediated immune responses can be effectively enhanced for the prevention or treatment of AIDS or cervical cancer. | 03-10-2011 |
| 20110070260 | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use - The invention provides immunogenic formulations comprising virus-like particles (VLPs) from two or more genoclusters and/or strains of norovirus in a pharmaceutically acceptable carrier. In representative embodiments, the formulation also comprises an adjuvant, for example, a viral adjuvant or CpG. The invention also provides methods of inducing an immune response to one or more noroviruses. | 03-24-2011 |
| 20110081377 | AEROSOLIZED GENETIC VACCINES AND METHODS OF USE - The present invention generally features methods for the mucosal delivery of immunogenic compositions and methods for treating or preventing diseases featuring such immunogenic compositions. In particular embodiments, the immunogenic compositions are genetic vaccines formulated as aerosols. | 04-07-2011 |
| 20110097358 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) - Respiratory syncytial virus (RSV) virus-like particles (VLPs) comprising at least one RSV protein are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs. | 04-28-2011 |
| 20110110973 | Influenza B Vaccines - This invention relates to immunogenic compositions including influenza B virus sequences, and methods of using such compositions. | 05-12-2011 |
| 20110129493 | COMBINED MEASLES-HUMAN PAPILLOMA VACINE - The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost. | 06-02-2011 |
| 20110159034 | METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A CD8 T CELL IMMUNE RESPONSE - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 06-30-2011 |
| 20110171253 | NOVEL ASTROVIRUS - This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes. | 07-14-2011 |
| 20110189226 | Immunization Compositions and Methods - The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus. | 08-04-2011 |
| 20110280904 | Generation of virus-like particles and use as panfilovirus vaccine - In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburs with lipid rafts during assembly and budding, and the requirement of functional rafts for entry of filoviruses into cells. | 11-17-2011 |
| 20110305726 | Infectious Bronchitis Vaccines Derived From IB-qx-like Vaccine Strains - The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses. | 12-15-2011 |
| 20120027795 | SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES - Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein. | 02-02-2012 |
| 20120064115 | RECOMBINANT VIRUS-LIKE PARTICLES ENCODED BY MULTI-GENE VECTOR - The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface. | 03-15-2012 |
| 20120201848 | ISOLATION OF A VIRUS RELATED TO CANINE PARVOVIRUS-2 FROM A RACCOON - Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins. | 08-09-2012 |
| 20120207782 | HIV DNA VACCINE REGULATED BY A CAEV-DERIVED PROMOTER - The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3′ LTR. | 08-16-2012 |
| 20120237543 | EQUINE RHINITIS VACCINE - The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. | 09-20-2012 |
| 20120269848 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTION - This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism are also included. | 10-25-2012 |
| 20120294891 | MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION - The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans. | 11-22-2012 |
| 20120321663 | LIVE VACCINE FOR AVIAN DISEASES - A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion. | 12-20-2012 |
| 20120328651 | CHIMPANZEE ADENOVIRUS VACCINE CARRIERS - The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer. | 12-27-2012 |
| 20130011433 | DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1, 2, 3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 4 - The invention relates to a dengue virus tetravalent vaccine containing a common | 01-10-2013 |
| 20130064848 | HETEROCHAIN ALIPHATIC POLY-N-OXIDE COPOLYMERS AND VACCINATING AGENTS AND DRUGS BASED THEREON - Heterochain aliphatic poly-N-oxide copolymers of general formula (1), where R═N, CH; x=2 or 4; y=0 or 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n, exhibit pharmacological activity, including an antioxidant effect and a therapeutic effect as a detoxicant and immunomodulating agent. The copolymer may be used as vaccinating agent also comprising an antigen and a vaccine against hepatitis A and hepatitis B, which contains a vaccine preparation comprising HVA Ag and HBsAg simultaneously or vaccine preparations against hepatitis A and against hepatitis B. The invention represents a new class of compounds that exhibit a wide range of pharmacological activity and a vaccination effect as well as increased safety in use, and is directed towards increasing manufacturability, cost efficiency and environmental safety in the production of drugs. | 03-14-2013 |
| 20130129779 | CATTLE REPRODUCTIVE DISEASE VACCINES - The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI | 05-23-2013 |
| 20130149334 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 06-13-2013 |
| 20130209507 | Rotavirus Subunit Vaccines and Methods of Making and Use Thereof - The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides. | 08-15-2013 |
| 20130280293 | COMBINATION HEPTAVALENT VACCINE - The invention provides a stable immunogenic composition for prevention and prophylaxis of infections caused by rota virus, poliomyelitis virus, | 10-24-2013 |
| 20130280294 | BOVINE VIRAL DIARRHEA VIRUS TYPE 1B VACCINE COMPOSITIONS AND METHODS - Disclosed are immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, managing, and/or ameliorating a viral or microbial infection, or one or more symptoms thereof, including, for example, those infections giving rise to shipping fever, bovine respiratory disease complex, and/or bovine viral diarrhea, particularly in susceptible or infected animals. | 10-24-2013 |
| 20140093535 | COMBINED VACCINES FOR PREVENTION OF PORCINE VIRUS INFECTIONS - The present disclosure provides vaccine compositions comprising a PRRSV vaccine and a second porcine vaccine, which are substantially free from immuno-inhibition against each other. The second porcine virus vaccine can be CSFV and/or PRV. The preparation methods for the vaccines and the formulations are also provided. The vaccine compositions provided herein confer protective immunity to pigs against porcine reproductive and respiratory syndrome, classical swine fever, and/or pseudorabies. | 04-03-2014 |
| 20140141040 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 05-22-2014 |
| 20140220073 | Immunization Compositions and Methods - The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus. | 08-07-2014 |
| 20140314806 | POTENCY TEST FOR VACCINE FORMULATIONS - The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen. | 10-23-2014 |
| 20150056247 | Sequential and repeated immunization with four or more vector-based HIV gene vaccines - The present invention provides a combined AIDS vaccine for preventing and/or treating AIDS, which consists of four or more different vector-based AIDS vaccines, wherein HIV protein gene comprised in the different AIDS vaccines may be same. A use method of the vaccine comprises inoculation of one AIDS vaccine each time, wherein inoculation of each vaccine may be continuously performed twice, and after sequential application of the four or more vector vaccines, repeated sequential application of the vector vaccines may be performed | 02-26-2015 |
| 20150098965 | MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION - The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans. | 04-09-2015 |
| 20160000902 | COMBINATION VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA - The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory syncytial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components. | 01-07-2016 |
| 20160008458 | CONDITIONALLY REPLICATION DEFICIENT HERPES VIRUS AND USE THEREOF IN VACCINES | 01-14-2016 |
| 20160129103 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 05-12-2016 |
| 20160129106 | Method for preparing virosomes - This disclosure relates to methods for preparing a virosome preparation comprising viral envelope protein of at least two, preferably at least three, more preferably at least four, different enveloped viruses, as well as to virosomal preparations obtained thereby. The disclosure also relates to the use of the virosomal preparations, e.g., as a vaccine. | 05-12-2016 |
| 20160151479 | METHOD FOR PREPARING VIROSOMES | 06-02-2016 |
| 20160199480 | METHOD FOR PREPARING VIROSOMES | 07-14-2016 |
| 20190142933 | THERAPEUTIC HPV VACCINE COMBINATIONS | 05-16-2019 |
